The opportunity to experience less pain

Significantly less pain and better mobility compared with on-demand (no prophylaxis)* bypassing therapy. 

After 25 weeks on HEMLIBRA, adults (18 and older) with FVIII inhibitors evaluated their hemophilia-related symptoms and physical functioning using a questionnaire widely recognized by the medical community. General symptoms of pain were not measured.

FVIII=factor VIII.

*Individuals did not receive prophylactic bypassing therapy.

Become a patient ambassador

HEMLIBRA Connections, a program sponsored by Genentech, is composed of real patients and their caregivers who share their stories with HEMLIBRA in hopes of educating others. They connect through educational activities to inform and inspire the broader hemophilia A community.

Learn more here.

Patient Stories

See real patients talk about their experience with HEMLIBRA

Find Your Clinical Educator

Get connected with your local Clinical Educator

Treating Breakthrough Bleeds

Making a plan